Brief: Sequana Medical: Positive Top-Line Results From SAHARA Ph.2A Study Of DSR 1.0

Sequana Medical NV

15/11/2022 06:09

Nov 15 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES POSITIVE TOP-LINE RESULTS FROM
SAHARA
PH. 2A STUDY OF DSR 1.0 IN DIURETIC-RESISTANT HEART FAILURE
PATIENTS WITH PERSISTENT CONGESTION AND FIRST PATIENT DOSED
SUCCESSFULLY WITH DSR 2.0 IN YUKON
    * CONSIDERABLE BENEFIT IN CARDIO-RENAL STATUS MAINTAINED
TILL END
OF STUDY (16 WEEKS POST-INTENSIVE DSR THERAPY)
    * DRAMATIC AND SUSTAINED IMPROVEMENT IN DIURETIC RESPONSEUP
TO 15
MONTHS POST INTENSIVE DSR THERAPY
    * NO CONGESTION-RELATED HEART FAILURE RE-HOSPITALIZATIONS
DURING
ENTIRE STUDY
    * ONE CLASS IMPROVEMENT OF NYHA STATUS AND 75% REDUCTION IN
PREDICTED ONE-YEAR MORTALITY BASED ON SEATTLE HEART FAILURE
MODEL
    * FIRST PATIENT DOSED SUCCESSFULLYIN YUKON, PH. 1 STUDY OF
SECOND-GENERATION DSR PRODUCT (DSR 2.0)
    * MOJAVE, US PH. 1/2A RANDOMIZED CONTROLLED
MULTI-CENTERSTUDY OF
DSR 2.0, ON TRACK TO START IN H1 2023
    * APPROVAL OF US IND WILL ENABLE COMPANY TO START MOJAVE,
ITS
RANDOMIZED CONTROLLED MULTI-CENTER PHASE 1/2A US STUDY OF DSR
2.0, PLANNED FOR H1 2023
    * ON TRACK TO START MOJAVE WITH DSR 2.0 IN H1 2023
    * INTERIM DATA OF MOJAVE ARE PLANNED FOR H2 2023 AND
TOP-LINE
RESULTS ARE EXPECTED IN MID 2024

Source text for Eikon:  ID:nGNE3fyBz9 
Further company coverage:  SEQUA.BR 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))